TY - JOUR
T1 - The glasgow prognostic score determined during concurrent chemoradiotherapy is an independent predictor of survival for cervical cancer
AU - Nishida, Takeshi
AU - Nakamura, Keiichiro
AU - Haraga, Junko
AU - Ogawa, Chikako
AU - Kusumoto, Tomoyuki
AU - Seki, Noriko
AU - Masuyama, Hisashi
AU - Katayama, Norihisa
AU - Kanazawa, Susumu
AU - Hiramatsu, Yuji
N1 - Publisher Copyright:
© 2015 by IGCS and ESGO.
PY - 2015/9/5
Y1 - 2015/9/5
N2 - Objective The Glasgow prognostic score (GPS) determined at pretreatment is important in the prediction of prognosis in various cancers. We investigated if the GPS used both at pretreatment and during concurrent chemoradiotherapy (CCRT) could predict the prognosis of patients with cervical cancer. Methods We collected GPS and clinicopathological data from the medical records of 91 patients who underwent CCRT for cervical cancer; their GPSs at pretreatment and during CCRT were retrospectively analyzed for correlations with recurrence and survival. Statistical analyses were performed using the Mann-Whitney U test. Disease-free survival (DFS) and overall survival (OS) were analyzed using the Kaplan-Meier method. Cox's proportional hazard regression was used for univariate and multivariate analyses. Results The median follow-up for all patients who were alive at the time of last follow-up was 38.0 months (range, 1-108 months). The DFS and OS rates of patients with a high GPS during CCRT (GPS 1 + 2; 55 patients; 60.4%) were significantly shorter than those for patients with a low GPS (GPS 0; 36 patients; 39.6%) (DFS, P < 0.001; OS, P < 0.001). Furthermore, multivariate analyses showed that high GPS during CCRT was an independent prognostic factor of survival for OS (P = 0.008). Conclusions During CCRT, a high GPS was revealed to be an important predictor of survival for cervical cancer.
AB - Objective The Glasgow prognostic score (GPS) determined at pretreatment is important in the prediction of prognosis in various cancers. We investigated if the GPS used both at pretreatment and during concurrent chemoradiotherapy (CCRT) could predict the prognosis of patients with cervical cancer. Methods We collected GPS and clinicopathological data from the medical records of 91 patients who underwent CCRT for cervical cancer; their GPSs at pretreatment and during CCRT were retrospectively analyzed for correlations with recurrence and survival. Statistical analyses were performed using the Mann-Whitney U test. Disease-free survival (DFS) and overall survival (OS) were analyzed using the Kaplan-Meier method. Cox's proportional hazard regression was used for univariate and multivariate analyses. Results The median follow-up for all patients who were alive at the time of last follow-up was 38.0 months (range, 1-108 months). The DFS and OS rates of patients with a high GPS during CCRT (GPS 1 + 2; 55 patients; 60.4%) were significantly shorter than those for patients with a low GPS (GPS 0; 36 patients; 39.6%) (DFS, P < 0.001; OS, P < 0.001). Furthermore, multivariate analyses showed that high GPS during CCRT was an independent prognostic factor of survival for OS (P = 0.008). Conclusions During CCRT, a high GPS was revealed to be an important predictor of survival for cervical cancer.
KW - Cervical cancer
KW - During concurrent chemoradiotherapy
KW - Glasgow prognostic score
KW - Predictor for poor prognosis
UR - http://www.scopus.com/inward/record.url?scp=84940922693&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940922693&partnerID=8YFLogxK
U2 - 10.1097/IGC.0000000000000485
DO - 10.1097/IGC.0000000000000485
M3 - Article
C2 - 26067860
AN - SCOPUS:84940922693
VL - 25
SP - 1306
EP - 1314
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
SN - 1048-891X
IS - 7
ER -
